EGFP-encoding Oncolytic Vaccinia Virus Western Reserve (ΔK3L), pSE/L-(EGFP)(Cat#: RepOV-0050WQ)

This product is a EGFP encoding oncolytic vaccinia virus, which is based on VACV-WR with K3L deleted. Binding of CXCL10 to CXCR3 results in pleiotropic effects, including stimulation of monocytes, natural killer and T-cell migration, and modulation of adhesion molecule expression. The deletion of K3L and CXCL10 expression could enhance the immune activity. This product can be used in oncolytic virotherapy research and vaccinie application.

Specifications

Family Poxviridae
Species Vaccinia virus
Serotype Western Reserve
Backbone VACV-WR(ΔK3L)
Backbone Background VACV-WR strain derived from Wyeth through passaging in mice and shown high tumor selectivity and strong oncolytic effect in mouse models.The engineered VACV-WR could further enhance the immune activity and the efficacy of cancer therapies.
Gene Modification ΔK3L
Promoter pSE/L
Transgene EGFP
Type of Transgene Reporter gene
Related Target/Protein Enhanced green fluorescent protein
Capsid Modification None
Titer >1*10^8 PFU
Related Diseases Breast cancer, Prostate cancer, Colon cancer, Cancer vaccine

Transgene

Alternative Names EGFP, egfp, enhanced green fluorescent protein
Gene ID 20473140

Information

Introduction EGFP, derived from Aequorea victoria, is a unique GFP variant which contains chromophore mutations that make the protein 35 times brighter than wild-type GFP, and is codon-optimized for higher expression in mammalian cells. These changes in the GFP coding sequence provide an enhanced GFP (EGFP) that greatly increases the sensitivity of the reporter protein.

Customer Reviews and Q&As

There are currently no customer reviews or questions for EGFP-encoding Oncolytic Vaccinia Virus Western Reserve (ΔK3L), pSE/L-(EGFP) (RepOV-0050WQ). Click the button below to contact us or submit your feedback about this product.

All products and services are for Research Use Only. Not For Clinical Use.

Other products

PRODUCTS

Online Inquiry